Ramiro Gilardino, MD, MHS began his healthcare career 20 years ago in Argentina. Shortly after obtaining his board certification in Critical Care Medicine, he became interested in understanding how clinical perspectives could enhance healthcare decision making. He transitioned to work as an outcomes researcher within the Ministry of Health in Argentina. Subsequently, he moved to the corporate sector, where he held positions at Johnson & Johnson Medical Devices, Omnicom Health Group, BMS, and currently at MSD (known as Merck & Co. Inc, in the United States and Canada), where he serves as the Global Access and Health Technology Assessment (HTA) Policy Leader within the International Market Access organization.
He is interested in research and execution of patient-centered value analysis, assessment of medical technologies, HTA policies in emerging countries, patient involvement in decision-making processes, and strengthening policies to support universal health coverage.
Dr Gilardino currently serves at the Center for Innovation in Regulatory Science HTA advisory board and is a steering committee member of the HTAi Rare Disease Interest Group and has served as an independent advisor to Decide Health® and acted as a regional advisor to the Americas Health Foundation. He contributed to the COVID-19 Health Financing Forum led by the World Bank and to the Partnerships for Health Financing Initiative. Currently, he serves as an associate editor of the International Journal of Technology Assessment in Health Care and the editorial board of ISPOR´s Value & Outcomes Spotlight, while also holding a faculty position at the Universidad de Buenos Aires School of Public Health.
With a history of strong ISPOR involvement, he was a founding member the Argentinean Pharmacoeconomics Association/ISPOR Argentinean Chapter and elected to chair the Latin America Consortium Health Technology Developers Committee. From 2016-2019 he joined ISPOR staff, as director for global networks LATAM supporting HEOR advancement in LMICs through conference developments, policy summits, and HEOR/HTA trainings; then as director for content strategies he fostered global partnerships with the World Health Organization and contributed to the ISPOR “Future of HEOR” white paper as part of the Strategic Plan Update 2024. He continues to actively contribute to ISPOR initiatives, serving on the Health Equity Special Interest Group leadership team and participating in various conference roles such as reviewer, judge, and recently as program committee member for ISPOR Europe 2022 and 2023.
Dr Gilardino's academic qualifications include an MD from the Universidad Abierta Interamericana, a master’s degree in economics and health management from the Universidad ISALUD, and a master of science in global public health from The London School of Hygiene and Tropical Medicine.
ISPOR Vision Statement by Ramiro Gilardino
Exciting times lie ahead for both HEOR and ISPOR as the Society enters its third decade with a strong strategic focus on scientific and research excellence, member engagement, education and training, and communication and collaboration. ISPOR has established itself as the leading society for health economics and outcomes research. My background as a clinician and global health policy advocate equips me to contribute to these pillars, supporting ISPOR’s goal of leading ongoing innovation in HEOR and promoting its global impact. Through my involvement in various global initiatives and leadership roles within ISPOR, I am well prepared to support member engagement efforts, fostering collaboration and networking opportunities for our members. Additionally, my experience in global health initiatives and editorial roles demonstrates my ability to effectively communicate and collaborate on important healthcare issues, furthering ISPOR's efforts to promote the value of HEOR and empower members as effective communicators.
As we approach the forthcoming Strategic Plan update for 2030, allow me to outline a few actions that, as a Board Director, I will support for the benefit of our Society:
Promoting Diversity and Inclusion in our HEOR Community: In alignment with ISPOR's mission, I recognize the importance of promoting diversity and inclusion within our HEOR community. As a Director, I will actively support initiatives to ensure that our community reflects diverse perspectives and experiences from various backgrounds and geographical regions. I will continue to champion the Women in HEOR initiative, building upon the work initiated by former “Women in HEOR leaders” who served as role models for me.
Championing Health Equity: I firmly believe in the potential of HEOR to bridge gaps in healthcare decisions, particularly in underserved populations and low- to middle-income countries (LMICs). As a Director, I am committed to advocating for health equity within ISPOR, emphasizing its importance across all initiatives and activities.
Advocating for LMICs' Involvement: ISPOR's global community is a key component in achieving its mission and strategic plan. I recognize the importance of ensuring that our members, especially those from LMICs, have a voice in shaping ISPOR's future strategies. I will work to nurture their perspectives and embed them in our deliverables.
Strengthening ISPOR's Global Position: I will actively foster collaborations to expand ISPOR's reach and amplify our influence in shaping global healthcare decisions. Drawing upon my involvement with other groups, I am committed to building robust relationships with global organizations, civil society, and scientific organizations to advance healthcare decisions worldwide.